HRP20200415T1 - Anti-ceacam5 protutijela i njihova uporaba - Google Patents
Anti-ceacam5 protutijela i njihova uporaba Download PDFInfo
- Publication number
- HRP20200415T1 HRP20200415T1 HRP20200415TT HRP20200415T HRP20200415T1 HR P20200415 T1 HRP20200415 T1 HR P20200415T1 HR P20200415T T HRP20200415T T HR P20200415TT HR P20200415 T HRP20200415 T HR P20200415T HR P20200415 T1 HRP20200415 T1 HR P20200415T1
- Authority
- HR
- Croatia
- Prior art keywords
- sequence
- antibody
- immunoconjugate
- seq
- cancer
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 claims 18
- 238000000034 method Methods 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- -1 4-methyl-4-mercapto-1-oxopentyl Chemical group 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- UQVNRKBFAXNOGA-OHLDGCSVSA-N (Z)-tomaymycin Chemical compound CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C/C)C[C@@H]12 UQVNRKBFAXNOGA-OHLDGCSVSA-N 0.000 claims 1
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims 1
- NNPUPCNWEHWRPW-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 239000012624 DNA alkylating agent Substances 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 241000863480 Vinca Species 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical class CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Claims (22)
1. Protutijelo koje sadrži teški lanac i laki lanac naznačeno time što varijabilna domena teškog lanca sadrži sekvencu SEQ ID NO: 5, ili sekvencu koja je najmanje 85% identična s njom, CDR1-H od sekvence SEQ ID NO:7, CDR2-H od sekvence SEQ ID NO:8, i CDR3-H od sekvence SEQ ID NO:9, te varijabilna domena lakog lanca sadrži sekvencu SEQ ID NO: 29, ili sekvencu koja je najmanje 85% identična s njom, CDR1-L od sekvence SEQ ID NO:10, CDR2-L od sekvence NTR i CDR3-L od sekvence SEQ ID NO:12.
2. Protutijelo prema patentnom zahtjevu 1 naznačeno time što varijabilna domena teškog lanca sadrži sekvencu SEQ ID NO: 5, ili sekvencu koja je najmanje 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% ili 99% identična s njom.
3. Protutijelo prema patentnom zahtjevu 1 naznačeno time što varijabilna domena lakog lanca sadrži sekvencu SEQ ID NO: 29, ili sekvencu koja je najmanje 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% ili 99% identična s njom.
4. Protutijelo prema patentnom zahtjevu 1 naznačeno time što protutijelo sadrži teški lanac koji sadrži sekvencu SEQ ID NO:87, ili sekvencu koja je najmanje 85% identična s njom, te laki lanac koji sadrži sekvencu SEQ ID NO:88, ili sekvencu koja je najmanje 85% identična s njom.
5. Izolirana nukleinska kiselina naznačena time što sadrži sekvencu koja kodira protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4.
6. Stanica domaćin naznačena time što je transformirana nukleinskom kiselinom prema patentnom zahtjevu 5.
7. Imunokonjugat naznačen time što sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4 konjugirano ili vezano na najmanje jedno sredstvo za inhibiciju rasta.
8. Imunokonjugat prema patentnom zahtjevu 7, naznačen time što je navedeno sredstvo za inhibiciju rasta citotoksično sredstvo ili radioaktivni izotop.
9. Imunokonjugat prema patentnom zahtjevu 7 ili 8, naznačen time što je navedeno sredstvo za inhibiciju rasta odabrano iz skupine koju čine kemoterapeutska sredstva, enzimi, antibiotici, i toksini kao što su toksini malih molekula ili enzimatski aktivni toksini, taksoidi, vinka, taksani, majtanzinoid ili analozi majtanzinoida, tomamicin ili derivati pirolobenzodiazepina, derivati kriptoficina, derivati leptomicina, analozi auristatina ili dolastatina, predlijekovi, inhibitori topoizomeraze II, DNA alkilirajuća sredstva, anti-tubulinska sredstva, te analozi CC-1065 ili CC-1065.
10. Imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 9, naznačen time što je navedeno sredstvo za inhibiciju rasta (N2'-deacetil-N2'-(3-merkapto-1-oksopropil)-majtanzin) DM1 ili N2'-deacetil-N-2'(4-metil-4-merkapto-1-oksopentil)-majtanzin (DM4).
11. Imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 10, naznačen time što je protutijelo kovalentno vezano preko cijepajućeg ili ne-cijepajućeg linkera na najmanje jedno sredstvo za inhibiciju rasta.
12. Imunokonjugat prema patentnom zahtjevu 11, naznačen time što je navedeni linker odabran iz skupine koju čine N-sukcinimidil piridilditiobutirat (SPDB), 4-(piridin-2-ildisulfanil)-2-sulfo-maslačna kiselina (sulfo-SPDB), i sukcinimidil (N-maleimidometil) cikloheksan-1-karboksilat (SMCC).
13. Imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 11 naznačen time što je protutijelo kovalentno vezano putem N-sukcinimidil piridilditiobutirata (SPDB) na N2'-deacetil-N-2'(4-metil-4-merkapto-1-oksopentil)-majtanzin (DM4).
14. Imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 13 naznačen time što protutijelo sadrži teški lanac koji sadrži sekvencu SEQ ID NO:87 i laki lanac koji sadrži sekvencu SEQ ID NO:88 i kovalentno je vezano putem N-sukcinimidil piridilditiobutirata (SPDB) na N2'-deacetil-N-2'(4-metil-4-merkapto-1-oksopentil)-majtanzin (DM4).
15. Farmaceutski pripravak naznačen time što sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4 ili imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 14, te farmaceutski prihvatljiv nosač.
16. Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4, ili imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 14, ili farmaceutski pripravak prema patentnom zahtjevu 15, naznačen time što je za uporabu za liječenje raka.
17. Protutijelo ili imunokonjugat prema patentnom zahtjevu 16 naznačen time što rak je rak debelog crijeva, želuca, gastrični rak ili rak pluća.
18. Postupak za proizvodnju protutijela prema bilo kojem od patentnih zahtjeva 1 do 4, koji postupak obuhvaća korake koji se sastoje od: (i) kultiviranja transformirane stanice domaćina prema patentnom zahtjevu 6; (ii) eksprimiranje navedenog protutijela ili polipeptida; i (iii) izdvajanje eksprimiranog protutijela ili polipeptida.
19. Postupak prema patentnom zahtjevu 18 naznačen time što je navedeno protutijelo prikladno odvojeno iz medija za kultiviranje konvencionalnim postupcima pročišćavanja imunoglobulina.
20. Postupak za proizvodnju imunokonjugata ili imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 14 naznačen time što sadrži korake (i) dovođenje u kontakt po izboru puferirane vodene otopine protutijela prema bilo kojem od patentnih zahtjeva 1 do 4 s otopinama poveznice i citotoksičnog spoja, i (ii) zatim izborno odvajanje konjugata koji je nastao u (i) iz nereagiranog protutijela.
21. Postupak za proizvodnju imunokonjugata ili imunokonjugat prema patentnom zahtjevu 20 naznačen time što se nakon koraka (i) ili (ii), otopina koja sadrži konjugat može podvrgnuti dodatnom koraku (iii) kromatografije, ultrafiltracije i/ili diafiltracije.
22. Postupak za pripremu farmaceutskog pripravka koji sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4 ili dobivenog postupkom prema patentnim zahtjevima 18 ili 19, ili imunokonjugat prema bilo kojem od patentnih zahtjeva 7 do 14 ili dobivenog postupkom prema patentnim zahtjevima 20 ili 21, naznačen time što je učinkovita količina navedenog protutijela ili navedenog imunokonjugata otopljena ili dispergirana u farmaceutski prihvatljivom nosaču ili vodenom mediju.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12306444 | 2012-11-20 | ||
EP17157890.9A EP3199552B1 (en) | 2012-11-20 | 2013-11-20 | Anti-ceacam5 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200415T1 true HRP20200415T1 (hr) | 2020-06-26 |
Family
ID=47257727
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170743TT HRP20170743T1 (hr) | 2012-11-20 | 2017-05-17 | Anti-ceacam5 protutijela i njihova uporaba |
HRP20200415TT HRP20200415T1 (hr) | 2012-11-20 | 2020-03-13 | Anti-ceacam5 protutijela i njihova uporaba |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170743TT HRP20170743T1 (hr) | 2012-11-20 | 2017-05-17 | Anti-ceacam5 protutijela i njihova uporaba |
Country Status (39)
Country | Link |
---|---|
US (4) | US9617345B2 (hr) |
EP (3) | EP3594243A1 (hr) |
JP (1) | JP6324399B2 (hr) |
KR (3) | KR102661801B1 (hr) |
CN (2) | CN109180815B (hr) |
AR (1) | AR093557A1 (hr) |
AU (2) | AU2013349733C1 (hr) |
BR (1) | BR112015010993B1 (hr) |
CA (2) | CA3207769A1 (hr) |
CL (1) | CL2015001321A1 (hr) |
CR (1) | CR20150258A (hr) |
CY (1) | CY1119219T1 (hr) |
DK (2) | DK2922875T3 (hr) |
DO (1) | DOP2015000110A (hr) |
EA (1) | EA039377B1 (hr) |
EC (1) | ECSP15025845A (hr) |
ES (2) | ES2778823T3 (hr) |
HK (1) | HK1215444A1 (hr) |
HR (2) | HRP20170743T1 (hr) |
HU (1) | HUE033369T2 (hr) |
IL (1) | IL238559B (hr) |
LT (2) | LT2922875T (hr) |
MA (1) | MA38194B1 (hr) |
MX (1) | MX358321B (hr) |
MY (1) | MY171100A (hr) |
NZ (1) | NZ708528A (hr) |
PE (1) | PE20151180A1 (hr) |
PH (1) | PH12015501092B1 (hr) |
PL (2) | PL2922875T3 (hr) |
PT (2) | PT3199552T (hr) |
RS (2) | RS60043B1 (hr) |
SG (1) | SG11201503285TA (hr) |
SI (2) | SI3199552T1 (hr) |
TN (1) | TN2015000177A1 (hr) |
TW (2) | TWI664192B (hr) |
UA (1) | UA120247C2 (hr) |
UY (1) | UY35147A (hr) |
WO (1) | WO2014079886A1 (hr) |
ZA (1) | ZA201502959B (hr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI664192B (zh) | 2012-11-20 | 2019-07-01 | 法商賽諾菲公司 | 抗ceacam5抗體及其用途 |
US9753036B2 (en) | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
CN113842468A (zh) * | 2014-09-02 | 2021-12-28 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
AU2016329111A1 (en) | 2015-10-02 | 2018-02-08 | F. Hoffmann-La Roche Ag | Bispecific anti-CEAXCD3 T cell activating antigen binding molecules |
EP3400246B1 (en) | 2016-01-08 | 2020-10-21 | H. Hoffnabb-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
AU2017343377A1 (en) * | 2016-10-10 | 2019-05-02 | Agency For Science, Technology And Research | Anti-CEACAM6 antibodies and methods of use |
AU2017360168B2 (en) | 2016-11-18 | 2023-10-12 | Astellas Pharma Inc. | Novel anti-human MUC1 antibody Fab fragment |
CN106749667B (zh) * | 2016-12-04 | 2020-07-14 | 深圳市国创纳米抗体技术有限公司 | 一种抗癌胚抗原的纳米抗体及其应用 |
CN108341876B (zh) * | 2017-01-22 | 2021-06-04 | 中国人民解放军第四军医大学 | 抗人ceacam5单克隆抗体及其制备方法和应用 |
CN106946989B (zh) * | 2017-03-02 | 2020-02-18 | 深圳市国创纳米抗体技术有限公司 | 抗cea抗原vhh结构域及含有其的双特异性抗体 |
TWI795415B (zh) * | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
JP7028953B2 (ja) * | 2017-07-11 | 2022-03-02 | ファイザー・インク | Cea、muc1およびtertを含む免疫原性組成物 |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
CA3093477A1 (en) | 2018-03-13 | 2019-09-19 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
EP3781592A4 (en) * | 2018-04-20 | 2023-01-11 | The Regents of the University of California | TREATMENT OF PROSTATE CANCER WITH CHIMERIC ANTIGEN RECEPTORS |
KR20210029158A (ko) | 2018-06-03 | 2021-03-15 | 람카프 바이오 베타 엘티디. | Ceacam5 및 cd47에 대한 이중특이성 항체 |
CN110684107B (zh) * | 2018-07-06 | 2021-03-23 | 中国人民解放军第四军医大学 | 抗MG7-Ag的单克隆抗体(MGd1)及其用途 |
CN110684108B (zh) * | 2018-07-06 | 2021-06-04 | 中国人民解放军第四军医大学 | 抗MG7-Ag的单克隆抗体(CEA37)及其用途 |
CA3109139A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
JP7407822B2 (ja) | 2018-08-30 | 2024-01-04 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 単鎖キメラポリペプチドおよびその使用 |
US20210355233A1 (en) * | 2018-10-10 | 2021-11-18 | Astellas Pharma Inc. | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
CN111487411B (zh) * | 2019-01-29 | 2023-05-09 | 瑞博奥(广州)生物科技股份有限公司 | Ceacam1多肽的新应用 |
EP3693023A1 (en) | 2019-02-11 | 2020-08-12 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
KR20210124260A (ko) | 2019-02-07 | 2021-10-14 | 사노피 | 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도 |
WO2020216847A1 (en) * | 2019-04-23 | 2020-10-29 | Sanofi | Stable, low-viscosity antibody formulations and uses thereof |
US20220242968A1 (en) * | 2019-06-04 | 2022-08-04 | Biotheus Inc. | Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
EP3983082A1 (en) | 2019-06-13 | 2022-04-20 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
AU2020294797A1 (en) | 2019-06-21 | 2021-12-23 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
WO2020260326A1 (en) | 2019-06-27 | 2020-12-30 | F. Hoffmann-La Roche Ag | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them |
EP4025254A1 (en) | 2019-09-03 | 2022-07-13 | Bolt Biotherapeutics, Inc. | Aminoquinoline compounds, immunoconjugates, and uses thereof |
WO2021053587A1 (en) | 2019-09-18 | 2021-03-25 | Klaus Strein | Bispecific antibodies against ceacam5 and cd3 |
US20220347310A1 (en) | 2019-09-30 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
BR112022007719A2 (pt) | 2019-10-25 | 2022-07-12 | Bolt Biotherapeutics Inc | Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
AU2021219720A1 (en) | 2020-02-11 | 2022-08-04 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
WO2021163369A2 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
CN115427083A (zh) | 2020-04-24 | 2022-12-02 | 赛诺菲 | 含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合 |
AU2021260823A1 (en) | 2020-04-24 | 2023-01-05 | Sanofi | Antitumor combinations containing anti-CEACAM5 antibody conjugates and FOLFOX |
IL297221A (en) | 2020-04-24 | 2022-12-01 | Sanofi Sa | Antitumor combinations containing conjugates of antibodies to ceacam5 and folfiri |
MX2022013404A (es) | 2020-04-24 | 2022-11-14 | Sanofi Sa | Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo. |
WO2021222587A1 (en) | 2020-04-29 | 2021-11-04 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
JP2023524271A (ja) | 2020-05-08 | 2023-06-09 | ボルト バイオセラピューティクス、インコーポレーテッド | エラスターゼ-基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用 |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
EP4157460A1 (en) | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
CN111690061B (zh) * | 2020-06-28 | 2022-08-23 | 中国人民解放军东部战区疾病预防控制中心 | 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用 |
CN113201070B (zh) * | 2020-08-04 | 2022-04-01 | 中山大学附属第五医院 | 抗ceacam5纳米抗体 |
KR20230051189A (ko) | 2020-08-13 | 2023-04-17 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 피라졸로아제핀 면역접합체, 및 그의 용도 |
IL300497A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Compositions and methods for treating CEACAM-positive cancer |
WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
US20220202946A1 (en) * | 2020-11-10 | 2022-06-30 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
WO2022116079A1 (zh) * | 2020-12-03 | 2022-06-09 | 上海吉倍生物技术有限公司 | 一种抗ceacam5的人源化抗体及其制备方法和用途 |
US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
JP2024501453A (ja) | 2020-12-11 | 2024-01-12 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ceaイムノコンジュゲート、及びそれらの使用 |
CN112521509B (zh) * | 2020-12-23 | 2022-07-08 | 姚雪英 | 一种抗ceacam5人源化抗体、其缀合物及其用途 |
IL306114A (en) | 2021-03-26 | 2023-11-01 | Bolt Biotherapeutics Inc | 2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof |
CN117769439A (zh) | 2021-03-26 | 2024-03-26 | 博尔特生物治疗药物有限公司 | 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途 |
CN117396516A (zh) * | 2021-05-21 | 2024-01-12 | 百济神州有限公司 | 抗cea抗体和使用方法 |
WO2023057564A1 (en) | 2021-10-07 | 2023-04-13 | Sanofi | IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS |
CA3237142A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies |
WO2023099682A1 (en) | 2021-12-02 | 2023-06-08 | Sanofi | Ceacam5 adc–anti-pd1/pd-l1 combination therapy |
TW202339804A (zh) | 2021-12-02 | 2023-10-16 | 法商賽諾菲公司 | 在癌症療法中用於患者選擇的cea測定 |
WO2023164610A2 (en) * | 2022-02-25 | 2023-08-31 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2b antibodies |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
TW202346354A (zh) * | 2022-03-09 | 2023-12-01 | 德商馬克專利公司 | 抗ceacam5抗體及其結合物及用途 |
WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
US20240124607A1 (en) | 2022-08-10 | 2024-04-18 | Merck Sharp & Dohme Llc | Proteins binding nkg2d, cd16, and ceacam5 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4640A (en) | 1846-07-14 | Book-lock | ||
US144A (en) | 1837-03-11 | Improvement in scythe-snaths | ||
US5204A (en) | 1847-07-24 | james cantelo | ||
US244A (en) | 1837-06-30 | Edward flint | ||
US4301A (en) | 1845-12-11 | Ebenezbr barrows | ||
US417A (en) | 1837-09-28 | Endless-ghain horse-power for driving iviaci-iii | ||
US4670A (en) | 1846-07-28 | Improvement in fish-hooks | ||
US835A (en) | 1838-07-12 | X i i i x | ||
US689A (en) | 1838-04-13 | Julius austin | ||
US4496A (en) | 1846-05-02 | Machinery for | ||
US4791A (en) | 1846-10-03 | john g | ||
US192A (en) | 1837-05-15 | Machine for cutting | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
ATE283926T1 (de) | 1995-09-11 | 2004-12-15 | Kyowa Hakko Kogyo Kk | Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO1998045322A2 (en) | 1997-04-10 | 1998-10-15 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method and reagents |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
ATE499116T1 (de) | 2002-08-16 | 2011-03-15 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
EP1618181B1 (en) | 2003-04-22 | 2014-10-15 | IBC Pharmaceuticals | Polyvalent protein complex |
JP5399712B2 (ja) | 2005-12-21 | 2014-01-29 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 可溶性ceaに対する抵抗性を有する医薬組成物 |
ME00581B (me) | 2006-07-18 | 2011-12-20 | Sanofi Aventis | Antagonisticna antitijela za tretman kancera polje pronalaska |
MY150531A (en) | 2007-07-16 | 2014-01-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
SG10201407388XA (en) | 2007-08-29 | 2015-01-29 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
PT2281006T (pt) | 2008-04-30 | 2017-12-06 | Immunogen Inc | Agentes de reticulação e as suas utilizações |
IN2012DN01663A (hr) * | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
DK2681244T3 (da) * | 2011-03-02 | 2018-01-29 | Roche Glycart Ag | Cea-antistoffer |
US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
TWI664192B (zh) | 2012-11-20 | 2019-07-01 | 法商賽諾菲公司 | 抗ceacam5抗體及其用途 |
US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
CN104948958A (zh) * | 2015-07-01 | 2015-09-30 | 上海顿格电子贸易有限公司 | 一种利用热敏电阻限流的led灯 |
CN108341876B (zh) * | 2017-01-22 | 2021-06-04 | 中国人民解放军第四军医大学 | 抗人ceacam5单克隆抗体及其制备方法和应用 |
AU2019292580A1 (en) * | 2018-06-29 | 2021-02-04 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
-
2013
- 2013-11-20 TW TW102142388A patent/TWI664192B/zh active
- 2013-11-20 KR KR1020227019435A patent/KR102661801B1/ko active IP Right Grant
- 2013-11-20 PT PT171578909T patent/PT3199552T/pt unknown
- 2013-11-20 PL PL13794894T patent/PL2922875T3/pl unknown
- 2013-11-20 RS RS20200296A patent/RS60043B1/sr unknown
- 2013-11-20 KR KR1020207036400A patent/KR102408660B1/ko active IP Right Grant
- 2013-11-20 DK DK13794894.9T patent/DK2922875T3/en active
- 2013-11-20 EP EP19181036.5A patent/EP3594243A1/en active Pending
- 2013-11-20 AR ARP130104276A patent/AR093557A1/es active IP Right Grant
- 2013-11-20 NZ NZ708528A patent/NZ708528A/en unknown
- 2013-11-20 BR BR112015010993-4A patent/BR112015010993B1/pt active IP Right Grant
- 2013-11-20 UA UAA201506107A patent/UA120247C2/uk unknown
- 2013-11-20 PL PL17157890T patent/PL3199552T3/pl unknown
- 2013-11-20 MX MX2015006374A patent/MX358321B/es active IP Right Grant
- 2013-11-20 RS RS20170498A patent/RS55987B1/sr unknown
- 2013-11-20 CN CN201810935038.6A patent/CN109180815B/zh active Active
- 2013-11-20 CA CA3207769A patent/CA3207769A1/en active Pending
- 2013-11-20 DK DK17157890.9T patent/DK3199552T3/da active
- 2013-11-20 MA MA38194A patent/MA38194B1/fr unknown
- 2013-11-20 SI SI201331696T patent/SI3199552T1/sl unknown
- 2013-11-20 EA EA201590986A patent/EA039377B1/ru unknown
- 2013-11-20 CN CN201380070899.8A patent/CN104918958B/zh active Active
- 2013-11-20 ES ES17157890T patent/ES2778823T3/es active Active
- 2013-11-20 CA CA2889962A patent/CA2889962C/en active Active
- 2013-11-20 MY MYPI2015001084A patent/MY171100A/en unknown
- 2013-11-20 UY UY0001035147A patent/UY35147A/es unknown
- 2013-11-20 PT PT137948949T patent/PT2922875T/pt unknown
- 2013-11-20 SG SG11201503285TA patent/SG11201503285TA/en unknown
- 2013-11-20 PE PE2015000631A patent/PE20151180A1/es active IP Right Grant
- 2013-11-20 AU AU2013349733A patent/AU2013349733C1/en active Active
- 2013-11-20 ES ES13794894.9T patent/ES2625742T3/es active Active
- 2013-11-20 LT LTEP13794894.9T patent/LT2922875T/lt unknown
- 2013-11-20 EP EP13794894.9A patent/EP2922875B1/en active Active
- 2013-11-20 TW TW108102332A patent/TW201940519A/zh unknown
- 2013-11-20 JP JP2015542313A patent/JP6324399B2/ja active Active
- 2013-11-20 LT LTEP17157890.9T patent/LT3199552T/lt unknown
- 2013-11-20 KR KR1020157015250A patent/KR102194748B1/ko active IP Right Grant
- 2013-11-20 SI SI201330653A patent/SI2922875T1/sl unknown
- 2013-11-20 WO PCT/EP2013/074291 patent/WO2014079886A1/en active Application Filing
- 2013-11-20 EP EP17157890.9A patent/EP3199552B1/en active Active
- 2013-11-20 HU HUE13794894A patent/HUE033369T2/en unknown
-
2015
- 2015-04-29 ZA ZA2015/02959A patent/ZA201502959B/en unknown
- 2015-04-30 IL IL238559A patent/IL238559B/en active IP Right Grant
- 2015-05-07 TN TNP2015000177A patent/TN2015000177A1/fr unknown
- 2015-05-14 DO DO2015000110A patent/DOP2015000110A/es unknown
- 2015-05-15 CR CR20150258A patent/CR20150258A/es unknown
- 2015-05-15 CL CL2015001321A patent/CL2015001321A1/es unknown
- 2015-05-15 PH PH12015501092A patent/PH12015501092B1/en unknown
- 2015-05-19 US US14/716,377 patent/US9617345B2/en active Active
- 2015-06-17 EC ECIEPI201525845A patent/ECSP15025845A/es unknown
-
2016
- 2016-03-23 HK HK16103384.0A patent/HK1215444A1/zh unknown
-
2017
- 2017-03-01 US US15/446,465 patent/US10457739B2/en active Active
- 2017-05-17 HR HRP20170743TT patent/HRP20170743T1/hr unknown
- 2017-06-15 CY CY20171100630T patent/CY1119219T1/el unknown
-
2018
- 2018-11-22 AU AU2018267636A patent/AU2018267636A1/en not_active Abandoned
-
2019
- 2019-09-03 US US16/558,939 patent/US11332542B2/en active Active
-
2020
- 2020-03-13 HR HRP20200415TT patent/HRP20200415T1/hr unknown
-
2022
- 2022-03-25 US US17/705,016 patent/US20220340682A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200415T1 (hr) | Anti-ceacam5 protutijela i njihova uporaba | |
HRP20191688T1 (hr) | Cd37-vezujuće molekule i njihovi imunokonjugati | |
JP6870051B2 (ja) | エリブリンをベースとする抗体−薬物コンジュゲート及び使用方法 | |
JP2015510761A5 (hr) | ||
RU2504553C2 (ru) | Антитела к her | |
JP6328649B2 (ja) | 薬物−タンパク質コンジュゲート | |
RU2012135395A (ru) | Антитела против рецептора фолиевой кислоты 1, их иммуноконъюгаты и использование | |
JP2013519375A5 (hr) | ||
HRP20210410T1 (hr) | Konjugirana antitijela prema ly75 za liječenje raka | |
US20130137659A1 (en) | Anticancer derivatives, preparation thereof and therapeutic use thereof | |
JP2016512832A5 (hr) | ||
CN112218663A (zh) | 剪接调节抗体-药物缀合物及其使用方法 | |
JP2008532523A5 (hr) | ||
MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
MX339927B (es) | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. | |
RU2009136946A (ru) | Композиции и способы диагностики и лечения опухоли | |
EA027925B1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
WO2010009124A3 (en) | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | |
JPS58208238A (ja) | 共有結合によつて酵素と抗体を結合させる新しい共役物とこの共役物を用いた医薬会合 | |
MY171008A (en) | Preparation of maytansinoid antibody conjugates by a one-step process | |
RU2008152431A (ru) | Антитела и иммуноконъюгаты и их применения | |
JP2016503295A5 (hr) | ||
WO2008091911A8 (en) | Use of antibody conjugates | |
JP2021530436A (ja) | Axlを標的とする抗体および抗体−薬物複合体ならびにその製造方法と使用 | |
JP2022512401A (ja) | ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 |